Belgium Breast Cancer Therapeutics Market Report 2022 to 2030

Belgium Breast Cancer Therapeutics Market Analysis

$ 3999

The higher success rates of breast cancer therapeutics are leading to the growth of Belgium's breast cancer therapeutics market from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the key market players in Belgium breast cancer therapeutics are Alter Pharma Group, Odyssea Pharma, and Bristol-Myers Squibb.

ID: IN10BEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Parul Choudhary

Buy Now

Belgium Breast Cancer Therapeutics Market Executive Analysis

The Belgium breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. With a health budget of 10.7% of GDP in 2021, Belgium ranks among the top ten European Union countries in terms of health spending. Household out-of-pocket spending on healthcare amounted to 18.2% of total spending, with the majority of that proportion going toward extra charges, official co-payments, and non-reimbursed treatments. The health and life expectancy of the Belgian people are excellent. This is in part because the public has easy access to a wide range of high-quality healthcare services. Major changes are anticipated to be made to the health system in Belgium during the coming years in order to maintain the high standard of care provided. Continuing the hospital landscape reform, mental health care changes, integrated care projects, creating a national health research system, and updating the national fee schedule are a few of them.

Belgium has one of the highest rates of breast cancer in Europe, with 9.697 new cases in 2008 and 106/100.000 women diagnosed per year. The aggregation of risk factors and the effects of screening and case registration are likely to blame for the high incidence in our nation. With 19,4/100.000 women per year and a 15-year all-stages survival rate of 75%, Belgium marginally outperforms the European average for breast cancer mortality. 3% of Belgian women's fatalities from all causes are due to breast cancer. Complex diagnostic algorithms are being built using new biomarker combinations in Denmark. The standard of care for neoadjuvant combination therapy, which frequently consists of targeted medicines, is the counter of surgery in the breast and axilla as well as the foundation for risk-adapted post-neoadjuvant therapies (particularly in HER2-positive and triple-negative breast cancer). Radiotherapy is still a crucial component of breast cancer treatment. Depending on the tumor type and molecular profile, typical therapy options for metastatic breast cancer include targeted therapies including CDK4 and CDK6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PD-L1 immunotherapy.

Market Dynamics

Market Growth Drivers

For Belgium's breast cancer therapeutics market, the development of therapeutics with higher success rates is predicted to present profitable growth prospects. Pharmacies are becoming more interested in this area despite the hefty expenditures of research and development. This is anticipated to provide the Belgian market for breast cancer therapies with excellent potential.

Market Restraints

Some individuals may find it difficult to afford breast cancer treatment, and the market growth for breast cancer therapies in Belgium may be hampered by patients' and healthcare professionals' lack of knowledge about the various treatment alternatives for breast cancer.

Competitive Landscape

Key Players

Horus Pharma Belux (BEL)
Inovet (BEL)
Alter Pharma Group (BEL)
Odyssea Pharma (BEL)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

The national healthcare system of Belgium provides coverage for breast cancer therapy. The foundation of the healthcare system is a legally required social insurance program, which is supported by a mix of company and employee contributions as well as general tax revenue. Through the public health care system, Belgian citizens have easy access to a variety of breast cancer services and treatments for little or no out-of-pocket expense. Depending on the type of treatment, different reimbursement policies apply; some may be entirely paid, while others may only be partially covered, and some may even call for co-payments. The national health care system and the national government set reimbursement policies in order to guarantee that people have access to the required medical care and that the expenses are reasonable for the patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.